Early Stage Health Technology Assessment for Precision Biomarkers in Oral Health and Systems Medicine

por Steuten, Lotte M.G.
Publicado en OMICS (2016)

A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers

por Oosterhoff, Marije, van der Maas, Marloes E., Steuten, Lotte M. G.
Publicado en Appl Health Econ Health Policy (2015)

Shifting breast cancer surveillance from current hospital setting to a community based setting: a cost-effectiveness study

por de Ligt, Kelly M., Witteveen, Annemieke, Siesling, Sabine, Steuten, Lotte M. G.
Publicado en BMC Cancer (2018)

Cost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands

por Miquel-Cases, Anna, Steuten, Lotte M. G., Rigter, Lisanne S., van Harten, Wim H.
Publicado en BMC Cancer (2016)

Quality of integrated chronic care measured by patient survey: identification, selection and application of most appropriate instruments

por Vrijhoef, Hubertus J. M., Berbee, Rieneke, Wagner, Edward H., Steuten, Lotte M. G.
Publicado en Health Expect (2009)

Cost-Effectiveness Analysis of a Procalcitonin-Guided Decision Algorithm for Antibiotic Stewardship Using Real-World U.S. Hospital Data

por Voermans, Anne M., Mewes, Janne C., Broyles, Michael R., Steuten, Lotte M. G.
Publicado en OMICS (2019)

Effectiveness of Multidimensional Cancer Survivor Rehabilitation and Cost-Effectiveness of Cancer Rehabilitation in General: A Systematic Review

por Mewes, Janne C., Steuten, Lotte M.G., IJzerman, Maarten J., van Harten, Wim H.
Publicado 2012

COPD as a multicomponent disease: Inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care

por Steuten, Lotte M.G., Creutzberg, Eva C., Vrijhoef, Hubertus J.M., Wouters, Emiel F.
Publicado en Prim Care Respir J (2006)

Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients

por Miquel-Cases, Anna, Retèl, Valesca P., Lederer, Bianca, von Minckwitz, Gunter, Steuten, Lotte M. G., van Harten, Wim H.
Publicado en PLoS One (2016)

Comparative cost-effectiveness of focal and total salvage (125)I brachytherapy for recurrent prostate cancer after primary radiotherapy

por Peters, Max, Piena, Marjanne A., Steuten, Lotte M.G., van der Voort van Zyp, Jochem R.N., Moerland, Marinus A., van Vulpen, Marco
Publicado en J Contemp Brachytherapy (2016)

A Call for Pharmacogenovigilance and Rapid Falsification in the Age of Big Data: Why not First Road Test Your Biomarker?

por Şardaş, Semra, Endrenyi, Laszlo, Gürsoy, Ulvi K., Hutz, Mara, Lin, Biaoyang, Patrinos, George P., Steuten, Lotte M.G., Wang, Wei, Warnich, Louise, Özdemir, Vural
Publicado en OMICS (2014)

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation

por Retèl, Valesca P., Steuten, Lotte M. G., Geukes Foppen, Marnix H., Mewes, Janne C., Lindenberg, Melanie A., Haanen, John B. A. G., van Harten, Wim H.
Publicado en BMC Cancer (2018)

Return-to-work intervention for cancer survivors: budget impact and allocation of costs and returns in the Netherlands and six major EU-countries

por Mewes, Janne C., Steuten, Lotte M. G., Groeneveld, Iris F., de Boer, Angela G. E. M., Frings-Dresen, Monique H. W., IJzerman, Maarten J., van Harten, Wim H.
Publicado en BMC Cancer (2015)

The Effectiveness of Chronic Care Management for Heart Failure: Meta-Regression Analyses to Explain the Heterogeneity in Outcomes

por Drewes, Hanneke W, Steuten, Lotte M G, Lemmens, Lidwien C, Baan, Caroline A, Boshuizen, Hendriek C, Elissen, Arianne M J, Lemmens, Karin M M, Meeuwissen, Jolanda A C, Vrijhoef, Hubertus J M
Publicado 2012